Robert W. Overell, PhD
President and CEO
Robert Overell is President and CEO of PhaseRx, which he founded to address the commercial need for effective siRNA delivery. He brings over 20 years of operational and venture investment experience to bear on this challenge. From 1997 until 2005 he was a General Partner with Frazier Healthcare Ventures where he participated in raising over $600M of venture capital and invested over $60M in private venture-backed biotechnology companies. His venture experience spans the spectrum of investment risks and stages, from seed to late stage investing. He was a key figure in the founding and/or growth of several venture-backed companies, including Array Biopharma (NASDAQ:ARRY), and XenoPort (NASDAQ:XNPT). His investments included therapeutics, tools, reagents, instrumentation, bioinformatics and service businesses.
Dr. Overell joined Immunex in 1984, where he built and led research and development programs in cell and molecular biology. At Immunex, he led the development, manufacturing and clinical affairs for the frst HIV gene therapy trial in the world, which was approved in 1991. Dr. Overell helped found the Immunex gene therapy spinout Targeted Genetics, where he directed the development of novel gene delivery vehicles from 1992 to 1996. Dr. Overell was trained as a cell and molecular biologist and has published numerous publications and patents, including a landmark paper on cell transformation in Nature in 1983. He obtained his PhD in Biochemistry from the Institute of Cancer Research, University of London, UK, and his BS in Biological Sciences from the University of Newcastle-upon-Tyne. He has served on numerous corporate boards, including SkeleTech, Array Biopharma (NASDAQ:ARRY), FastTrack, Chimerix, Quantum Dot,Inpharos, Gene Machines, and XenoPort (NASDAQ:XNPT). He also serves on the board and is the immediate past Chairman of YouthCare (see
© 2014 PhaseRx, Inc.     410 West Harrison Street, Suite 300, Seattle WA 98119     206.805.6300 Terms of Use Site Design